Neonatal neurobehavior effects following buprenorphine versus methadone exposure

Area of Science:

• Neonatal research
• Neuroscience
• Pharmacology

Background:

• Opioid use during pregnancy presents risks to infant neurobehavioral development.
• Neonatal Abstinence Syndrome (NAS) is a common consequence of in utero opioid exposure.
• Methadone and buprenorphine are common treatments for opioid dependence during pregnancy.

Purpose of the Study:

• To compare the neurobehavioral effects of in utero exposure to methadone versus buprenorphine in neonates.
• To assess infant neurobehavioral development in relation to NAS severity and treatment.

Main Methods:

• A substudy of the randomized clinical trial, Maternal Opioid Treatment: Human Experimental Research (MOTHER) study.
• Utilized the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale (NNNS) to assess neurobehavior in infants.
• Data collected on postpartum days 3, 5, 7, 10, 14-15, and 28-30.

Main Results:

• Infants exposed to buprenorphine demonstrated significantly fewer stress-abstinence signs, less excitability, and better self-regulation compared to those exposed to methadone.
• Higher self-regulation scores were observed in infants who started morphine treatment for withdrawal at a later age.
• Movement quality was negatively correlated with NAS severity, duration, and total morphine dose.

Conclusions:

• Buprenorphine exposure in utero leads to superior infant neurobehavioral outcomes compared to methadone.
• Neurobehavioral development improves in the first month of life for neonates exposed to agonist medications.
• Buprenorphine treatment may result in less severe withdrawal symptoms and better neurobehavioral profiles in infants.